Calumet, Inc. (NASDAQ: CLMT) today reported results of Calumet, Inc. (the "Company," "Calumet," "we," "our" or "us") for the second quarter ended June 30, 2025, as follows: ...

Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis ...

Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and nine month periods ended June 30, 2025. "Q3 was a strong ...

Calfrac generated Adjusted EBITDA of $77.0 million during the second quarter in 2025, a 39 percent increase from the first quarter in 2025, primarily due to improved utilization and financial ...